Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226,220,429
-
Total 13F shares
-
131,205,694
-
Share change
-
+8,982,579
-
Total reported value
-
$586,006,096
-
Put/Call ratio
-
47%
-
Price per share
-
$4.47
-
Number of holders
-
158
-
Value change
-
+$44,997,765
-
Number of buys
-
75
-
Number of sells
-
73
Institutional Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q1 2024
As of 31 Mar 2024,
Allogene Therapeutics, Inc. - Common Stock (ALLO) was held by
158 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
131,205,694 shares.
The largest 10 holders included
FMR LLC, TPG GP A, LLC, BlackRock Inc., STATE STREET CORP, VANGUARD GROUP INC, PRIMECAP MANAGEMENT CO/CA/, JPMORGAN CHASE & CO, PRICE T ROWE ASSOCIATES INC /MD/, Boxer Capital, LLC, and CITADEL ADVISORS LLC.
This page lists
158
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.